High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis.

ABSTRACT:

Background

ACE2 a key molecule of the Renin-Angiotensin system has been identified as the receptor for SARS-CoV-2 entry into human cells. In the context of human cancers, there is evidence that ACE2 might function as a tumor suppressor. The expression levels of ACE2 among the different subtypes of breast cancer has not been investigated.

Methods

We have examined the differential expression of ACE2 and its correlation with prognosis in breast cancer subtypes using the METABRIC (n = 1898) and TCGA (n = 832) cohorts. Correlations were evaluated by Pearsons's correlation co-efficient and Kaplan-Meier analysis was used to estimate differences in disease-free survival between the ACE2 high and ACE2 low groups.

Results

There is minimal expression of ACE2 in the luminal class

SUBMITTER: Nair MG 

PROVIDER: S-EPMC7825889 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature